Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012–2014  by Nakano, Satoshi et al.
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Pneumococcal  infection  in  children  is  a major  public  health  problem  worldwide,  including  in Japan.  The
pneumococcal  conjugate  vaccine  7 (PCV7)  was  licensed  for  use  in  Japan  in 2010  followed  by  PCV13  in
2013.  This report  includes  the results  of a nationwide  surveillance  of  invasive  pneumococcal  disease
(IPD)  and non-IPD  in paediatric  patients  from  January  2012  to December  2014.  We  collected  343 isolates
from  337  IPD  patients  and 286  isolates  from  278  non-IPD  patients.  Of the  IPD  isolates,  the  most  iden-
tiﬁed  serotypes  included  19A,  24F,  and  15A.  The  prevalence  of  non-PCV13  serotype  isolates  increased
signiﬁcantly  from  2012  to  2014 (51.6–71.4%,  p = 0.004).  Serotypes  19A,  15A and  35B were  highly  non-
susceptible  to penicillin,  and  the  rates  of non-susceptible  isolates  from  IPD patients  to  penicillin  and
cefotaxime  signiﬁcantly  declined  during  the  study  period  (p =  0.029  and  p =  0.013,  respectively).  The non-
susceptible  rate  to meropenem  increased,  particularly  for serotype  15A.  The  IPD isolates  comprised  clonal
complex  (CC)  3111  (93.8%  was  serotype  19A)  followed  by CC2572  (81.5%  was  serotype  24F)  and  CC63weden -25 clone
aediatric
(97.1%  was  serotype  15A).  CC3111,  CC63  and CC156  (33.3%  was  serotype  23A, 28.6%  was  serotype  6B,
and  14.3%  was  serotype  19A)  were  highly  non-susceptible  to penicillin.  Of the  non-IPD  isolates,  the most
identiﬁed  serotypes  included  19A,  15A,  and 3.  In conclusion,  the  introduction  of  PCV7  and  PCV13  resulted
in increasing  non-PCV13  serotypes  and clones,  including  antimicrobial  resistant  serotypes  15A  and  CC63
(Sweden15A-25  clone).. Introduction
Streptococcus pneumoniae is a common pathogen of bacterial
nfections in children and is associated with high morbidity and
ortality [1]. In 2000, an estimated 14.5 million serious infections
nd 826,000 deaths occurred in children younger than 5 years of
ge [2]. To protect children against invasive pneumococcal disease
∗ Corresponding author at: 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya
678602, Japan. Tel.: +81 52 852 8216; fax: +81 52 852 8216.
E-mail address: yutaka@med.nagoya-cu.ac.jp (Y. Ito).
ttp://dx.doi.org/10.1016/j.vaccine.2015.11.015
264-410X/© 2015 Elsevier Ltd. All rights reserved.©  2015  Elsevier  Ltd. All  rights  reserved.
(IPD), 7-, 10- and 13-valent pneumococcal conjugate vaccines were
licensed for use in children worldwide. The widespread use of these
vaccines has signiﬁcantly decreased the incidence of serious IPD in
children [3–9]. However, IPD continues to occur due to the emer-
gence of non-vaccine serotypes [10–13]. Therefore, surveillance of
pneumococcal infections including IPD is essential for monitor-
ing the beneﬁcial effects of pneumococcal conjugate vaccine (PCV)
implementation and its potential impact on the structure of the
pneumococcal population.
PCV7 was  licensed in Japan in February 2010 and was used on a
voluntary basis until April 2013. During this period, the estimated
rates of PCV7 vaccination in children under 5 years of age increased
68 S. Nakano et al. / Vaccine
Fig. 1. Distribution of Japanese institutions participating in the present surveillance
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ach prefecture.
rom <10% in 2010 to 80–90% in 2012 [4]. In April 2013, PCV7 was
pproved as a routine vaccination in Japan, and the vaccine was
witched to PCV13 in October 2013.
We  conducted a nationwide pneumococcal surveillance pro-
ramme  of children to review the epidemiology of IPD and other
neumococcal infections, including bacterial pneumonia and acute
titis media (non-IPD), and the shift of serotype distribution from
anuary 2012 to December 2014. Additionally, we clariﬁed the dis-
ribution of the susceptibility and sequence types of the isolates.
. Materials and methods
This study is a nationwide, ongoing, prospective surveillance of
neumococcal infections including IPD. This report presents data
rom a 3-year period (January 2012 through December 2014). The
tudy was approved by the Ethics Committee of the National Hospi-
al Organization Mie  National Hospital (acceptance number, 23-8).
nformed consent for collection and use of patient information and
pecimens was obtained from each parent/guardian by a primary
hysician.
.1. Study population and case deﬁnition
During the study period, a total of 154 medical institutions,
ncluding 20 private clinics, actively participated in the surveillance
Fig. 1). All of the study participants who were diagnosed with IPD,
neumonia and/or otitis media were under 16 years and over 2
onths of age. IPD was deﬁned as the recovery of S. pneumoniae
rom a culture of a normal sterile body ﬂuid, such as blood, cere-
rospinal ﬂuid (CSF), pleural effusion, and joint ﬂuid, regardless of
he identiﬁcation of S. pneumoniae from other non-sterile samples.
asically, a single isolate was submitted for each IPD case; how-
ver, if at least two isolates with different serotypes were identiﬁed
rom at least one appropriate sample (e.g., blood and cerebrospinal
uid), all of the isolates were submitted as one IPD case. If at least
wo isolates with the same serotype were identiﬁed from ster-
le and non-sterile samples (e.g., cerebrospinal ﬂuid and middle
ar ﬂuid), these were counted as one isolate, even though both
nfection sites (e.g., bacterial meningitis and otitis media) were sub-
itted for the IPD diagnosis in Table 1. In cases of bacteraemia with
ther organ infection caused by isolates with the same serotype,
he isolate from the original sterile infection site (e.g., cerebral 34 (2016) 67–76
spinal ﬂuid, joint ﬂuid, and pleural ﬂuid) was  submitted. Pneumo-
coccal pneumonia was diagnosed by clinical respiratory symptoms
compatible with the presence of acute pneumonia with the recov-
ery of S. pneumoniae from lower respiratory tract specimens. To
obtain an appropriate sputum sample, we  recommend perform-
ing a sputum induction with nebulized hypertonic saline or using
a suction catheter. A routine chest X-ray was  not needed at the
time of pneumonia diagnosis. If S. pneumoniae was isolated from
a sterile sample, such as blood, from a patient who  was  suspected
of having pneumococcal pneumonia, the case was  counted as only
IPD. Pneumococcal otitis media was  diagnosed by relevant clinical
ﬁndings with the recovery of S. pneumoniae from middle ear ﬂuid
obtained by myringotomy incision. A case with both pneumococcal
otitis media and pneumonia was  counted as a pneumococcal pneu-
monia case to avoid duplication in non-IPD. Similar to the criteria of
pneumococcal pneumonia with bacteraemia, if S. pneumoniae was
isolated from a sterile sample, such as blood, from a patient who
was suspected of having pneumococcal otitis media, the case was
counted as only IPD.
2.2. Data collection
A standardized questionnaire was  used to collect data on age,
sex, current diseases, past pneumococcal vaccination history, past
medical history and disease outcomes. Data were obtained by the
primary physician of each patient and sent to the surveillance ofﬁce.
2.3. Routine vaccination programme and vaccination rate
The Japanese routine vaccination programme recommends that
all infants are given a primary series of PCV at 2, 4, and 6 months
of age with a booster at 12–15 months of age. Children who fall
behind are recommended for catch-up vaccinations through 59
months of age. This recommended vaccination programme is com-
mon  among healthy and high-risk children. At the transition from
PCV7 to PCV13, PCV13 was used to complete the series of PCV7. For
children who had received a complete PCV7 schedule at the tran-
sition, a single supplemental dose of PCV13 was  not recommended
by the Japanese government.
Since the introduction of the Urgent Promotion of Vaccination
incentive by the Japanese government in 2011, the vaccination rate
in Japan has been increasing. According to previous reports, the
rates were 50–60% in 2011 and 89.2% in 2014 [4,14].
2.4. Identiﬁcation and serotyping
Pneumococcal identiﬁcation was  performed as described pre-
viously [15]. For serotyping, pneumococcal isolates were sent
to one of two reference laboratories, LSI Medience Corpora-
tion and National Institute of Infectious Diseases. Serotyping was
performed using pneumococcal typing antisera (Statens Serum
Institut, Copenhagen, Denmark).
2.5. Susceptibility testing
Susceptibility testing for penicillin, erythromycin, cefotaxime,
meropenem and levoﬂoxacin was performed on isolates using
the broth micro dilution method at LSI Medience Corporation.
We opted to use the Clinical and Laboratory Standards Insti-
tute (CLSI) guidelines because these were the standards in use
in Japan during the study period. In 2008, the CLSI changed the
recommended breakpoints to those currently used to interpret
minimum inhibitory concentration (MIC) values. For penicillin and
cefotaxime, we  used the 2008 CLSI recommended breakpoints for
meningitis, and for erythromycin, meropenem and levoﬂoxacin, we
used the 2008 CLSI recommended breakpoints for all infection sites
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Table  1
Characteristics of patients with IPD or non-IPD during the study period.
IPD, n (%) Non-IPD, n (%)
2012 2013 2014 Total 2012 2013 2014 Total
No. of isolates 64 153 126 343 70 134 82 286
No.  of patients 64 148 125 337 70 126 82 278
Patient characteristics
Age group
<12 months 20 (31.3) 30 (20.3) 18 (14.4) 68 (20.2) 15 (21.4) 28 (22.2) 19 (23.2) 62 (22.3)
12–23  months 23 (35.9) 71 (48.0) 49 (39.2) 143 (42.4) 27 (38.6) 61 (48.4) 42 (51.2) 130 (46.8)
2–4  years 16 (25.0) 36 (24.3) 51 (40.8) 103 (30.6) 28 (40.0) 37 (29.4) 21 (25.6) 86 (30.9)
5–15  years 5 (7.8) 11 (7.4) 7 (5.6) 23 (6.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Male  31 (48.4) 93 (62.8) 75 (60.0) 199 (59.1) 40 (57.1) 63 (50.0) 48 (58.5) 151 (54.3)
Total  no. of comorbidity 10 (17.2) 25 (16.9) 28 (22.4) 63 (18.7) 5 (7.1) 12 (9.5) 3 (3.7) 20 (7.2)
Congenital heart disease 3 (4.7) 6 (4.1) 10 (8.0) 19 (5.6) 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.4)
Chromosomal anomalies 2 (3.1) 6 (4.1) 4 (3.2) 12 (3.6) 0 (0.0) 1 (0.8) 0 (0.0) 1 (0.4)
Malignancy 3 (4.7) 2 (1.4) 2 (1.6) 7 (2.1) 0 (0.0) 0 (0.0) 0 (0.0)
Bronchial asthma 2 (3.1) 2 (1.4) 2 (1.6) 6 (1.8) 3 (4.3) 0 (0.0) 0 (0.0) 3 (1.1)
Others 1 (1.6) 11 (7.4) 10 (8.0) 22 (6.5) 2 (2.9) 10 (7.9) 3 (3.7) 15 (5.4)
Diagnosis
Primary bacteraemia 43 (67.2) 95 (64.2) 79 (63.2) 217 (64.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Meningitis 12 (18.7) 19a (12.9) 18c (14.4) 49 (14.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Arthritis 1 (1.6) 2 (1.4) 0 (0.0) 3 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pleuritis 0 (0.0) 1 (0.7) 1 (0.8) 2 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Peritonitis 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pneumoniaf 5 (7.8) 25b (16.9) 18 (14.4) 48 (14.2) 19 (27.1) 20 (15.9) 5e (6.1) 44 (15.8)
Otitis  mediaf 2 (3.1) 7a,b (4.7) 4d (3.2) 13 (3.9) 51 (72.9) 106 (84.1) 78e (95.1) 235 (84.5)
Other  infection sitesf 1 (1.6) 4 (2.7) 6c,d (4.8) 11 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Outcomes
Mortality 0 (0.0) 2 (1.4) 4 (3.2) 6 (1.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Sequelae 3 (4.7) 2 (1.4) 2 (2.5) 7 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Absence of information 1 (1.6) 6 (4.1) 4 (3.2) 11 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Completely cured 60 (93.8) 138 (93.2) 115 (92.0) 313 (92.9) 70 (100.0) 126 (100.0) 82 (100.0) 278 (100.0)
IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.
a Among the nine cases of bacteraemia with meningitis, one case was complicated by otitis media.
b Among the 25 cases of bacteraemia with pneumonia, four cases were complicated by otitis media.
c Among the 10 cases of bacteraemia with meningitis, one case was  complicated by infectious endocarditis.
d Among the four cases of otitis media with bacteraemia, one case was  complicated by bronchitis.
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16]. Isolates identiﬁed as intermediate or resistant were grouped
ogether as non-susceptible; for example, penicillin susceptible (S)
nd non-susceptible (NS) were deﬁned as (in mg/l) ≤0.06 and >0.06,
espectively. In the case of erythromycin, S and NS were deﬁned as
0.25 and >0.25, respectively, and for cefotaxime, S and NS were
eﬁned as ≤0.5 and >0.5, respectively. In addition, for meropenem,
 and NS were deﬁned as ≤0.25 and >0.25, respectively, and for
evoﬂoxacin, S and NS were deﬁned as ≤2 and >2, respectively. We
sed the same breakpoint criteria for IPD and non-IPD to facilitate
heir comparison with each other.
.6. Multi-locus sequence typing (MLST)
MLST was performed as described previously [17], and sequence
ypes (STs) were allocated using the MLST online database (www.
ubmlst.org). We  ran eBURST (http://eburst.mlst.net) with default
ettings, associating each sequence type (ST) with a clonal com-
lex (CC) deﬁned as a group of STs sharing six of seven loci on the
ntire MLST database and newly assigned STs within our database.
sing the Pneumococcal Molecular Epidemiology Network (PMEN)
atabase, we allocated the results of MLST for each PMEN clone..7. Statistical analysis
Data were analyzed using Microsoft Excel and Stata, version
3.0 (Statcorp, TX, USA). We  used the Cochran–Armitage trend test
o assess signiﬁcant differences in the serotype and susceptibility
istribution during the epidemiological years of 2012 to 2014.y otitis media.
d by bacteraemia.
3. Results
3.1. Patients and isolate collection
Between January 2012 (PCV7 era) and December 2014 (PCV13
era), we collected a total of 629 isolates (615 cases) from 154
medical institutions, including 20 private clinics in Japan. The par-
ticipating institutions were distributed into 38 of 47 prefectures
in Japan. Of these isolates, 343 isolates were derived from 337 IPD
patients, and 286 isolates were obtained from 278 non-IPD (pneu-
mococcal pneumonia and otitis media) patients (Table 1).
Of the IPD cases, 63 patients (18.7%) had comorbidity. The most
prevalent comorbidities were congenital heart disease (n = 19) fol-
lowed by chromosomal anomalies (n = 12), malignancy (n = 7), and
bronchial asthma (n = 6). Six subjects (1.8%) died, and seven sub-
jects (2.1%) had sequelae. In total, 313 subjects (92.9%) were cured
completely, and we did not have information for 11 (3.3%) of these
cases from a chief physician.
The immunization histories of PCV7 and PCV13 are described in
Table 2. Of the IPD cases in 2012, 42 (65.6%) did not receive PCV7.
The incomplete vaccination rate in IPD cases decreased over time
to 57 cases (45.6%) in 2014.
3.2. SerotypesWe identiﬁed 27 and 21 different capsular types in IPD and
non-IPD isolates, respectively (Fig. 2 and Table 3). Of the IPD iso-
lates (n = 343), the most frequent isolates included serotype 19A
(n = 95, 27.7%) followed by 24F (n = 51, 14.9%) and 15A (n = 36,
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Table 2
Numbers of completed routine vaccine schedule of PCV7 or PCV13 in each age group.
Disease Months
of age
Total no. of cases Complete PCV7 schedule, no. (%) Complete PCV13 schedule, no. (%) Incomplete PCV7 and
13 schedules, no. (%)
2012 2013 2014 2012 2013 2014 2012 2013 2014 2012 2013 2014
IPD 2–11 20 30a 18 12 (60.0) 26 (86.7) 6 (33.3) 0 (0.0) 0 (0.0) 6 (33.3) 8 (40.0) 3 (10.0) 6 (33.3)
12–23 23 71b 49 6 (26.1) 28 (39.4) 6 (12.2) 0 (0.0) 0 (0.0) 16 (32.7) 17 (73.9) 39 (54.9) 27 (55.1)
>23  21c 47d 58e 3(14.3) 19 (40.4) 28 (48.3) 0 (0.0) 0 (0.0) 3 (5.2) 17 (81.0) 27 (57.4) 24 (41.4)
Total 64 148 125 21 (32.8) 73 (49.3) 40 (32.0) 0 (0.0) 0 (0.0) 25 (20.0) 42 (65.6) 69 (46.6) 57 (45.6)
Non-IPD 2–11 15 28 19f 11 (73.3) 17 (60.7) 8 (42.1) 0 (0.0) 0 (0.0) 5 (26.3) 4 (26.7) 11 (39.3) 5 (26.3)
12–23 27 61g 42h 11 (40.7) 18 (29.5) 17 (40.5) 0 (0.0) 1 (1.6) 9 (21.4) 16 (38.1) 40 (65.6) 15 (35.7)
>23  28 37i 21 4 (14.3) 15 (40.5) 9 (42.9) 1 (3.6) 0 (0.0) 0 (0.0) 23 (82.1) 19 (51.4) 12 (57.1)
Total 70 126 82 25 (35.7) 48 (38.1) 34 (41.5) 1 (1.4) 1 (0.8) 14 (17.1) 44 (62.9) 72 (57.1) 32 (39.0)
For IPD and non-IPD, immunization information was  absent in a total of 10 and 7 cases, respectively.
The  complete course of PCV7 was  deﬁned by the numbers of PCV7 injections based on the Japanese schedule referring to the patient’s age in months.
The  complete course of PCV13 was deﬁned by the number of PCV13 injections based on the Japanese schedule referring to the patient’s age in months, including the transition
from  the PCV7 series to PCV13.
a,c,d,f,hIn one case, the vaccination information was missing.
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In four cases, the vaccination information was  missing.
In two  cases, the vaccination information was missing.
0.5%). From 2012 (PCV7 era) to 2014 (PCV13 era), serotypes
9F, 6B and 6A decreased signiﬁcantly (p = 0.002, p = 0.003, and
 = 0.041, respectively), and serotype 24F increased signiﬁcantly
p < 0.001). Of the non-IPD isolates (n = 286), the most frequent iso-
ates included serotypes 19A and 15A (n = 56, 19.6%) followed by 3
n = 33, 11.5%) and serotype 15B/C (n = 28, 9.8%). From 2012 to 2014,
erotype 15B/C decreased signiﬁcantly (p = 0.025), and serotype
5A increased signiﬁcantly (p = 0.003). In total, the identiﬁcation
ate of serotypes 19F and 6B decreased signiﬁcantly (p = 0.002 and
 = 0.005, respectively). In addition, serotypes 15A, 22F, and 24F
ncreased signiﬁcantly (p = 0.028, p = 0.041, and p < 0.001, respec-
ively) from 2012 to 2014.
Year-to-year changes in the prevalence of PCV and non-PCV
erotypes of S. pneumoniae are described in Table 3. The preva-
ence of non-PCV13 serotype isolates in IPD isolates and total
solates increased signiﬁcantly between 2012 and 2014 (p = 0.004
nd p = 0.001, respectively). The prevalence of PCV7 serotype in the
PD and total isolates decreased signiﬁcantly from 2012 to 2014
p < 0.001 and p < 0.001, respectively).
As regard to the relationship between PCV receipts and iden-
iﬁed serotypes, 41.3% of IPD cases with a non-PCV13 serotype
solate completely received PCV7 or PCV13 based on the Japanese
chedule, and 40.8% of the IPD cases with a PCV13 serotype iso-
ate completely received PCV7 or PCV13 based on the Japanese
chedule. With regard to 31 IPD patients who completely received
CV13, the numbers of each identiﬁed serotype were as fol-
ows: 11 cases of serotype 24F, ﬁve cases of serotypes 15A
nd 15B/C, three cases of serotype 24B, two cases of serotypes
9A and 22F, and one case each of serotypes 6A, 11A, and 38;
hus, 90.3% of these serotypes were not included in the PCV13
erotypes.
.3. Antimicrobial susceptibility
With regard to IPD isolates, non-IPD isolates, and total iso-
ates, the proportions of non-susceptible isolates to the tested
ntimicrobials are summarized in Fig. 3. Of the 629 total iso-
ates, the non-susceptible proportions were as follows: 46.1% to
enicillin, 20.2% to cefotaxime, 20.5% to meropenem, 94.3% to
rythromycin and 0.2% to levoﬂoxacin. Of the 127 isolates that were
on-susceptible to cefotaxime, 69 (54.3%) were non-susceptible
o meropenem. Serotype 19A, 15A and 35B isolates were highly
on-susceptible to penicillin (60.3%, 97.8% and 68.8%, respectively),
hereas all serotype 22F and 24F isolates were susceptible to peni-
illin. The non-susceptible proportions to penicillin and cefotaximedeclined during our study period; however, the decline was statis-
tically signiﬁcant for only cefotaxime from 2012 to 2014 (p = 0.316,
penicillin; p = 0.030, cefotaxime). However, if limited to only IPD
isolates, the declines in non-susceptible isolates to penicillin and
cefotaxime were signiﬁcant (p = 0.029, penicillin; p = 0.013, cefo-
taxime). Additionally, signiﬁcant increases were observed for the
non-susceptible proportion to meropenem in the non-IPD and total
isolates (p < 0.001, non-IPD isolates; p = 0.007, total isolates). Simi-
larly, the analysis of serotype 15A in the total isolates revealed that
the non-susceptible proportion to meropenem increased (p = 0.001,
serotype 15A).
3.4. MLST analysis
The distribution of STs of each serotype is described in Table 4.
All 629 isolates were separated into 125 different STs. eBURST anal-
yses clustered these STs into 51 CCs, including nine singletons. Of
the 343 IPD isolates, 80 (23.3%) were CC3111, which was the main
clone observed during the study period. Of these CC3111 isolates,
93.8% were serotype 19A, and one isolate (1.3%) was  of each of the
following serotypes: 10A, 15A, 24F, 34 and non-typeable. The sec-
ond and third most common clones were CC2572 (n = 54, 15.7%)
and CC63 (n = 34, 9.9%), respectively. Of the CC2572 isolates, 81.5%
were serotype 24F, and of the CC63 isolates, 97.1% were serotype
15A (Sweden15A-25 clone). The proportions of CC2572 and CC433
(all of CC433 were serotype 22F) increased signiﬁcantly (p < 0.001,
CC2572; p = 0.032, CC433) from 2012 to 2014, whereas the propor-
tion of CC156 decreased signiﬁcantly (p < 0.001) during this period.
The CC156 isolates presented some serotype heterogeneity: 33.3%
of serotype 23A, 28.6% of serotype 6B, and 14.3% of serotype 19A.
The non-susceptible proportions to penicillin of CC3111, CC2572,
CC63, CC433 and CC156 in the IPD isolates were 58.8%, 3.7%, 94.1%,
0.0% and 61.9%, respectively.
Of 286 non-IPD isolates, 55 (19.2%) were identiﬁed as CC63,
which was the main clone observed in the study period. In addi-
tion, 96.4% of the CC63 isolates were serotype 15A, and there was
one isolate (1.8%) each of serotype 11A and 23A. The second and
third most commonly observed clones were CC3111 (n = 44, 15.4%)
and CC180 (n = 32, 11.2%), respectively. In the CC180, 93.8% of the
isolates were serotype 3 (Netherlands3-31 clone). CC63 increased
signiﬁcantly between 2012 and 2014 (p < 0.001).The total isolates resistant to meropenem primarily consisted
of CC63 isolates followed by CC3111 and CC558 isolates. The non-
susceptible proportions of CC63, CC3111 and CC558 isolates to
meropenem were 69.7%, 16.1% and 90.9%, respectively.
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Fig. 2. Distribution of pneumococcal serotypes in Japan from 2012 (PCV7 era) to 2014 (PCV13 era). In Japan, PCV13 was approved as a routine vaccination in April 2013. NT,
non-typeable. The asterisk (*) indicates statistically signiﬁcant differences at p < 0.05, as determined through the Cochran–Armitage trend test. (a) IPD isolates. (b) Non-IPD
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.5. Mortality cases
During our surveillance period, six mortality cases were
bserved. These included three serotype 15A isolates and one case
ach of serotypes 22F, 23A and 10A; thus, all of these cases were
aused by non-PCV13 serotype isolates. In addition, all six cases
ith observed mortality had bacteraemia, although one case also
ad pneumococcal meningitis, another case also had pneumococ-
al pneumonia and a third case also had necrotizing cellulitis. The
ther three cases were diagnosed as primary bacteraemia. Five out
f the six cases had underlying disease: congenital heart disease
four cases) and cerebral palsy (one case). Four of the patients were
 years of age, and the other two patients were 16 and 31 months of
ge, respectively. In addition, two of the patients were administered
CV7 completely on schedule.4. Discussion
We conducted a nationwide surveillance programme of both
IPD and non-IPD including patient characteristics, serotype preva-
lence, antibiotic susceptibility, and ST prevalence in Japan between
2012 (PCV7 era) and 2014 (PCV13 era). This report is the ﬁrst in
the literature describing antimicrobial susceptibilities, including
meropenem and IPD patient characteristics, after the introduction
of PCV13 in Japan.
Various studies have reported the serotype distribution shift to
non-vaccine serotypes after the introduction of the pneumococcal
conjugate vaccine [10–13]. In Japan, Chiba et al. reported a PCV7
coverage rate of 14.7% in paediatric IPD isolates in 2012 [4]. Our data
indicated that the coverage rate in 2012 was 18.8%, which is simi-
lar to this report. Additionally, the signiﬁcant decrease in IPD due
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Table 3
Serotype distribution of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease (IPD) and non-IPD in Japan during 2012–2014.
Serotype Number (%) of IPD isolates Number (%) of non-IPD isolates Number (%) of total isolates
2012
(n = 64)
2013
(n = 153)
2014
(n = 126)
p  Value 2012
(n = 70)
2013
(n = 134)
2014
(n = 82)
p Value 2012
(n = 134)
2013
(n = 287)
2014
(n = 208)
p
Value
PCV7 serotypes
14 1 (1.6) 0 (0.0) 0 (0.0) 0.102 0 (0.0) 0 (0.0) 0 (0.0) NA 1 (0.7) 0 (0.0) 0 (0.0) 0.124
18C  1 (1.6) 1 (0.7) 0 (0.0) 0.181 0 (0.0) 0 (0.0) 0 (0.0) NA 1 (0.7) 1 (0.3) 0 (0.0) 0.229
19F  4 (6.3) 1 (0.7) 0 (0.0) 0.002 2 (2.9) 4 (3.0) 0 (0.0) 0.202 6 (4.5) 5 (1.7) 0 (0.0) 0.002
6B  6 (9.4) 4 (2.6) 1 (0.8) 0.003 2 (2.9) 0 (0.0) 1 (1.2) 0.369 8 (6.0) 4 (1.4) 2 (1.0) 0.005
23F  0 (0.0) 2 (1.3) 0 (0.0) 0.723 1 (1.4) 1 (0.7) 0 (0.0) 0.291 1 (0.7) 3 (1.0) 0 (0.0) 0.311
Total  of PCV7
serotypes
12 (18.8) 8 (5.2) 1 (0.8) <0.001 5 (7.1) 5 (3.7) 1 (1.2) 0.059 17 (12.7) 13 (4.5) 2 (1.0) <0.001
PCV13 serotypes
1 2 (3.1) 3 (2.0) 3 (2.4) 0.825 0 (0.0) 0 (0.0) 0 (0.0) NA 2 (1.5) 3 (1.0) 3 (1.4) 0.977
19A  15 (23.4) 49 (32.0) 31 (24.6) 0.845 17 (24.3) 25 (18.7) 14 (17.1) 0.273 32 (23.9) 74 (25.8) 45 (21.6) 0.541
6A  2 (3.1) 1 (0.7) 0 (0.0) 0.041 1 (1.4) 5 (3.7) 0 (0.0) 0.478 3 (2.2) 6 (2.1) 0 (0.0) 0.061
7F  0 (0.0) 2 (1.3) 0 (0.0) 0.723 0 (0.0) 0 (0.0) 0 (0.0) NA 0 (0.0) 2 (0.7) 0 (0.0) 0.819
3  0 (0.0) 0 (0.0) 1 (0.8) 0.256 5 (7.1) 21 (15.7) 7 (8.5) 0.876 5 (3.7) 21 (7.3) 8 (3.8) 0.809
Total  of additional
PCV13 serotypes
19 (29.7) 55 (35.9) 35 (27.8) 0.552 23 (32.9) 51 (38.1) 21 (25.6) 0.302 42 (31.3) 106 (36.9) 56 (26.9) 0.242
Total  of PCV13
serotypes
31 (48.4) 63 (41.2 36 (28.6) 0.004 28 (40.0) 56 (41.8) 22 (26.8) 0.079 59 (44.0) 119 (41.5) 58 (27.9) 0.001
Non-PCV13 serotypes
10A 0 (0.0) 5 (3.3) 5 (4.0) 0.156 2 (2.9) 3 (2.2) 4 (4.9) 0.450 2 (1.5) 8 (2.8) 9 (4.3) 0.127
11A  1 (1.6) 2 (1.3) 1 (0.8) 0.615 4 (5.7) 5 (3.7) 3 (3.7) 0.542 5 (3.7) 7 (2.4) 4 (1.9) 0.326
12F  0 (0.0) 1 (0.7) 0 (0.0) 0.802 0 (0.0) 0 (0.0) 0 (0.0) NA 0 (0.0) 1 (0.3) 0 (0.0) 0.872
15A  6 (9.4) 16 (10.5) 14 (11.1) 0.716 10 (14.3) 19 (14.2) 27 (32.9) 0.003 16 (11.9) 35 (12.2) 41 (19.7) 0.028
15B/C  5 (7.8) 12 (7.8) 10 (7.9) 0.974 13 (18.6) 9 (6.7) 6 (7.3) 0.025 18 (13.4) 21 (7.3) 16 (7.7) 0.101
20  0 (0.0) 0 (0.0) 1 (0.8) 0.256 0 (0.0) 0 (0.0) 0 (0.0) NA 0 (0.0) 0 (0.0) 1 (0.5) 0.225
22F  4 (6.3) 4 (2.6) 14 (11.1) 0.066 1 (1.4) 3 (2.2) 2 (2.4) 0.671 5 (3.7) 7 (2.4) 16 (7.7) 0.041
23A  3 (4.7) 1 (0.7) 3 (2.4) 0.503 2 (2.9) 6 (1.5) 2 (2.4) 0.853 5 (3.7) 7 (2.4) 5 (2.4) 0.499
24B  1 (1.6) 4 (2.6) 4 (3.2) 0.521 0 (0.0) 0 (0.0) 0 (0.0) NA 1 (0.7) 4 (1.4) 4 (1.9) 0.371
24F  2 (3.1) 21 (13.7) 28 (22.2) <0.001 1 (1.4) 2 (1.5) 1 (1.2) 0.908 3 (2.2) 23 (8.0) 29 (13.9) <0.001
33F  1 (1.6) 2 (1.3) 1 (0.8) 0.615 0 (0.0) 1 (0.7) 1 (1.2) 0.372 1 (0.7) 3 (1.0) 2 (1.0) 0.868
34  0 (0.0) 1 (0.7) 2 (1.6) 0.242 1 (1.4) 2 (1.5) 1 (1.2) 0.908 1 (0.7) 3 (1.0) 3 (1.4) 0.539
35B  3 (4.7) 7 (4.6) 4 (3.2) 0.563 1 (1.4) 10 (7.5) 7 (8.5) 0.079 4 (3.0) 17 (5.9) 11 (5.3) 0.420
37  0 (0.0) 0 (0.0) 0 (0.0) NA 0 (0.0) 1 (0.7) 1 (1.2) 0.372 0 (0.0) 1 (0.3) 1 (0.5) 0.457
38  3 (4.7) 6 (3.9) 1 (0.8) 0.091 0 (0.0) 7 (5.2) 0 (0.0) 0.877 3 (2.2) 13 (4.5) 1 (0.5) 0.177
6C  3 (4.7) 5 (3.3) 2 (1.6) 0.212 4 (5.7) 5 (3.7) 3 (3.7) 0.542 7 (5.2) 10 (3.5) 5 (2.4) 0.171
6D  0 (0.0) 0 (0.0) 0 (0.0) NA 1 (1.4) 0 (0.0) 0 (0.0) 0.152 1 (0.7) 0 (0.0) 0 (0.0) 0.124
7C  0 (0.0) 1 (0.7) 0 (0.0) 0.226 0 (0.0) 0 (0.0) 0 (0.0) NA 0 (0.0) 1 (0.3) 0 (0.0) 0.872
NT  1 (1.6) 2 (1.3) 0 (0.0) 0.215 2 (2.9) 5 (3.7) 2 (2.4) 0.861 3 (2.2) 7 (2.4) 2 (1.0) 0.334
Total  of non-PCV13 33 (51.6) 90 (58.8) 90 (71.4) 0.004 42 (60.0) 78 (58.2) 60 (73.2) 0.079 75 (56.0) 168 (58.5) 150 (72.1) 0.001
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o the PCV7 serotypes was observed in the following period in our
tudy. Consequently, PCV7 serotype isolates disappeared almost
ompletely in 2014 (PCV13 era). With regard to PCV13 serotypes,
he serotype coverage rate in IPD decreased signiﬁcantly from 2012
PCV7 era) to 2014 (PCV13 era) (p = 0.004). The coverage rate in
014 was 28.6%, which is equal to or slightly reduced compared
ith previous reports from other countries [5,7,8,18]. Of note, in
ur study, the coverage rate of PCV13 was already low (48.4% in
012) before the introduction of PCV13 in 2013. This rate was
aused by the prevalence of serotypes 15A, 15B/C and 24F, which
re not included in PCV 13 serotypes. A previous study in Japan
lso reported a low coverage rate of 39.1% in 2012 [4]. Regarding
he year-to-year changes in serotypes of IPD isolates, serotypes 24F
ncreased signiﬁcantly during the study periods. A previous study
rom Japan also reported the increase of serotypes 15A, 15B/C, 24F,
nd 22F [4]; therefore, we presume that these serotypes will be
revalent in Japan in the PCV13 era. A trend in serotype shift simi-
ar to that found in Japan has also been observed in other countries.
ecent studies conducted after the implementation of PCV13 have
ound the prevalence of serotypes 22F, 15B/C and 35B in the U.S.
19] and signiﬁcant increases in serotypes 15A and 24F in England
nd Wales [20]. These studies also reported a signiﬁcant decrease
n serotype 19A, which is of great concern given its antimicrobial
esistance. However, in our study, serotype 19A did not decrease
n the PCV13 era, even though serotype 19A is included in PCV13.This result is likely due to the short period since the introduction of
PCV13. In our study, the most common serotype, i.e., serotype 19A,
increased up to 2013 and then decreased in 2014, although this
decrease was  not signiﬁcant, which is likely due to the short period
of observation since the introduction of PCV13; in fact, the com-
pletely PCV13 immunization rate of IPD patients in 2014 was only
20.0%. Because 31 of the IPD cases that received a complete course of
PCV13 in the present study were due to mostly non-PCV13 serotype
isolates (90.3%), we  expect a decrease in the proportion serotype
19A isolates in the future based on the prevalence of PCV13 in Japan.
The MLST analysis clariﬁed a trend of prevalent genotypes of
pneumococcal isolates in Japan. The most prevalent CC in total
isolates in Japan was  CC3111, which primarily included serotype
19A. Approximately 60% of isolates of this clone were not suscep-
tible to penicillin. Serotype 19A CCs (199, 320/271, and 695) that
are notably resistant in the United States were not prevalent in
our region [19,21,22]. CC2572, which primarily included serotype
24F and was susceptible to penicillin, signiﬁcantly spread between
2012 and 2014. Therefore, this clone is predicted to spread further
in Japan because serotype 24F is not included in PCV13.
Previous studies reported that the introduction of PCV7 into
the National Immunization Programme (NIP) was associated with
a substantial decline in penicillin non-susceptible pneumococci
prevalence [21,23,24]. This decline is due to the decrease in resis-
tant clones and the increase in susceptible clones. In our study,
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Fig. 3. Year-to-year changes in the antimicrobial resistance rates to penicillin, cefotaxime, and meropenem of the major serotypes in IPD isolates and total isolates in Japan
from  2012 (PCV7 era) to 2014 (PCV13 era). In Japan, PCV13 was  approved as a routine vaccination in April 2013. The asterisk (*) indicates statistically signiﬁcant differences
at  p < 0.05, as determined through the Cochran–Armitage trend test. (a) Proportion of penicillin-non-susceptible IPD isolates. (b) Proportion of cefotaxime-non-susceptible
IPD  isolates. (c) Proportion of meropenem-non-susceptible IPD isolates. (d) Proportion of penicillin-non-susceptible non-IPD isolates. (e) Proportion of cefotaxime-non-
susceptible non-IPD isolates. (f) Proportion of meropenem-non-susceptible non-IPD isolates. (g) Proportion of penicillin-non-susceptible total isolates. (h) Proportion of
cefotaxime-non-susceptible total isolates. (i) Proportion of meropenem-non-susceptible total isolates.
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CV7 serotypes including serotypes 6B, 19F and 23F, which were
ot susceptible to penicillin, disappeared. In contrast, CC2572
erotype 24F, which is a non-PCV13 serotype and is suscepti-
le to penicillin, increased during the study period. Additionally,
ur study revealed that CC63 serotype 15A (Sweden15A-25 clone)
nd CC 558 serotype 35B, which are not susceptible to penicillin,
ppeared to spread in Japan. CC3111 serotype 19A, a portion of
hich exhibited a penicillin-resistant prevalence, did not decrease
uring our study period. As a result, the proportions of IPD iso-
ates that were non-susceptible to penicillin declined signiﬁcantly
uring the study period.
Notably, a signiﬁcant increase in the proportion of isolates non-usceptible to meropenem was observed in our study. Previous
tudies reported the proportion of S. pneumoniae non-susceptible
o carbapenems in other countries [25–28]. According to these
eports, the resistance rate appears to be higher in Asia comparedinued ).
with other regions. Few reports have referred to the correlation
between meropenem resistance and its genetic feature in the
post-PCV13 era. In our study, a high proportion of meropenem
resistance was observed in serotype 15A CC63 (Sweden15A-25
clone); therefore, we assumed that the increase in the meropenem
resistance rate was  caused by the spread of speciﬁc resistant CC63
with serotype 15A (Sweden15A-25 clone) isolates. Additionally, our
study found a high proportion of CC558 serotype 35B isolates were
non-susceptible to meropenem, which is similar to the ﬁnding
observed in the United States [19].
We  did not detect a relationship between serotypes and mortal-
ity or sequelae of IPD in the present study because the numbers of
mortality and sequelae cases were very low (Table 1). Easy access
to hospitals in Japan given the national insurance system may
have led to this outcome. Of note, most of mortality cases inves-
tigated in the present study had underlying disease. Although the
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Table  4
Distribution of sequence types (STs) and clonal complex (CC) in IPD and non-IPD
isolates.
Serotype (n) CC ST (n: PMEN clone)
6B (14) 156 90 (2: Spain6B-2), 2983 (2), 5497 (1),
9333 (1)
3787 2756 (1), 3787 (1)
66 902 (2), 2923 (1)
242 242 (1)
2224 9335 (1)
2924 1437 (1)
19F (11) 320 236 (7: Taiwan19F-14), 926 (1)
115 115 (1)
156 280 (1)
393 393 (1)
23F (4) 2924 1437 (3)
242 242 (1: Taiwan23F-15)
18C (2) 3594 3594 (2)
14 (1) 230 5240 (1)
19A (151) 3111 3111 (111), 7988 (1), 8339 (1), 9016
(1), 9334 (1), 10257 (1), new (1)
2331 2331 (11), 10252 (3), 5842 (2), 9647
(2), 5237 (1), 10260 (1)
156 338 (1), 3109 (1), 5242 (1), 5246 (1)
320 320 (4)
6429 6429 (2)
99 7811 (1)
199 199 (1)
558 558 (1)
2572 5496 (1)
3  (34) 180 180 (25: Netherlands3-31), 5234 (3),
4054 (1), 10246 (1), 10258 (1)
448 7494 (1)
1106 7803 (1)
Singleton 9336 (1)
6A (9) 3787 2756 (3), 3113 (2)
81 81 (1)
180 180 (1)
5832 5832 (1)
6429 6429 (1)
1  (8) 306 306 (8: Sweden1-28)
7F  (2) 191 191 (2: Netherlands7F-39)
15A  (92) 63 63 (52: Sweden15A-25), 10245 (11),
9084 (6), 7874 (3), 9646 (3), 10244 (2),
1621 (1), 2105 (1), 4532 (1), 4899 (1),
9617 (1), 9644 (1), 10256 (1), 10259
(1), new (2)
Singleton 10249 (1)
156 5246 (1)
292 292 (1)
2572 5496 (1)
3111 3111 (1)
15B/C (55) 199 199 (33: Netherlands15B-37), 10250
(5), 1531 (2), 7793 (2), 419 (1), 2704
(1), 3934 (1)
156 5242 (3), 9643 (1)
81 83 (3)
Singleton 9622 (1), 9648 (1), 9649 (1)
24F (55) 2572 2572 (30), 5496 (15), 7984 (1), 10022
(1), 10248 (1)
4982 4982 (4)
156 5241 (1)
3111 3111 (1)
Singleton 9621 (1)
35B (32) 558 558 (19), 10255 (1)
1816 2755 (10)
3111 3111 (1)
7786 7502 (1)
22F (28) 433 433 (20), 819 (1), 9288 (1), 10023 (1),
10026 (1), new (1)
113 5236 (2), 7158 (1)
6  C (22) 2924 2924 (4), 6183 (2), 10243 (1)
5832 5832 (6), 5025 (1)
156 5241 (3)
66 2923 (2)
63 63 (1)
242 242 (1)
Singleton 9336 (1)
Table 4 (Continued )
Serotype (n) CC ST (n: PMEN clone)
38 (17) 6429 6429 (8)
393 393 (4)
115 115 (1)
180 180 (1)
199 199 (1)
7786 7502 (1)
Singleton 9336 (1)
23A (17) 156 338 (9), 5242 (4), 5246 (2)
63 63 (1)
180 180 (1)
10A (19) 113 5236 (9), 10247 (1)
156 7810 (1), 10254 (1)
558 558 (1)
3111 3111 (1)
Singleton 10021 (1)
11A (16) 99 99 (12)
62 62 (2)
63 63 (1)
393 393 (1)
24B (9) 2572 2572 (4), 5496 (4)
2754 2754 (1)
34 (7) 1439 7388 (3)
3116 3116 (3)
3111 3111 (1)
33F (6) 717 717 (6)
37 (2) 447 447 (2)
12F (1) 1527 4846 (1)
6D (1) 81 282 (1)
7C (1) 2758 10251 (1)
Non-typeable
(12)
3111 3111 (2)
66 9642 (1)
113 5236 (1)
199 199 (1)
230 4845 (1), 10253 (1)
3116 3116 (2)
6429 6429 (1)
7834 7834 (1)
Singleton 7019 (1)
number of mortality cases was  very small, we should pay attention
to such patients with severe underlying disease for the prevention
and treatment of IPD.
The limitations of this study should be noted. Our study period
of surveillance during the PCV 13 era was  approximately 1 year,
which may  not be sufﬁcient time to observe the long-term impacts
of the introduction of PCV13. However, the present results showed
decreases in the proportion of PCV13 serotype isolates from 2013
to 2014 in IPD, which must be partly due to PCV13. Second,
our surveillance was not a population-based study but rather an
actively participating surveillance. The implement of our surveil-
lance was not well known throughout all of the institutions in Japan
in 2012, the ﬁrst year of the surveillance; therefore, the number of
IPD isolates collected in 2012 was less than those collected in the
other years. A previous surveillance in Japan reported a PCV7 cov-
erage rate of 14.7% in paediatric IPD isolates in 2012 [4], which
is similar to that found in our study (18.8%). We evenly collected
isolates from nationwide institutions throughout the surveillance
period; thus, we  believe that the data obtained from even the
small number of isolates collected in 2012 are reliable in terms
of serotype proportions and susceptibility distribution.
In conclusion, we  conducted a nationwide surveillance pro-
gramme  of IPD and non-IPD cases from 2012 (PCV7 era) to
2014 (PCV13 era). This surveillance revealed that IPD isolates
were mainly serotypes 19A, 24F, and 15A, and the serotype
distribution was  shifting to non-PCV13 serotypes continuously
during the PCV7 era and after the introduction of PCV13. The
proportion of IPD isolates non-susceptible to penicillin and cefo-
taxime declined signiﬁcantly during the study period, and the
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roportion of total isolates non-susceptible to meropenem
ncreased signiﬁcantly. The MLST analysis clariﬁed that CC3111, CC
572 and CC63 were the main clones in IPD isolates and that CC63
ith serotype 15A (Sweden15A-25 clone) was primarily associated
ith meropenem resistance. To control and prevent pneumococ-
al infections, a sustained surveillance and a multifaceted study to
dentify complicated trends of pneumococci are needed.
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